Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation.

Molinaro E, Leboeuf R, Shue B, Martorella AJ, Fleisher M, Larson S, Tuttle RM.

Thyroid. 2009 Oct;19(10):1035-41. doi: 10.1089/thy.2008.0430.

PMID:
19772430
2.

Influence of the first radioactive iodine ablation on peripheral complete blood count in patients with differentiated thyroid cancer.

Hu T, Meng Z, Zhang G, Jia Q, Tan J, Zheng W, Wang R, Li X, Liu N, Zhou P, Upadhyaya A.

Medicine (Baltimore). 2016 Aug;95(35):e4451. doi: 10.1097/MD.0000000000004451.

3.

Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation.

Grewal RK, Larson SM, Pentlow CE, Pentlow KS, Gonen M, Qualey R, Natbony L, Tuttle RM.

J Nucl Med. 2009 Oct;50(10):1605-10. doi: 10.2967/jnumed.108.061382. Epub 2009 Sep 16.

4.

Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.

Tuttle RM, Lopez N, Leboeuf R, Minkowitz SM, Grewal R, Brokhin M, Omry G, Larson S.

Thyroid. 2010 Mar;20(3):257-63. doi: 10.1089/thy.2009.0401.

PMID:
20187781
5.

Complete blood counts are frequently abnormal 1 year after dosimetry-guided radioactive iodine therapy for metastatic thyroid cancer.

Padovani RP, Tuttle RM, Grewal R, Larson SM, Boucai L.

Endocr Pract. 2014 Mar;20(3):213-20. doi: 10.4158/EP13172.OR.

PMID:
24126230
6.

Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.

Hugo J, Robenshtok E, Grewal R, Larson S, Tuttle RM.

Thyroid. 2012 Oct;22(10):1007-15. doi: 10.1089/thy.2012.0183. Epub 2012 Aug 8.

PMID:
22873801
7.

Thyroid lobe ablation with radioactive iodine as an alternative to completion thyroidectomy after hemithyroidectomy in patients with follicular thyroid carcinoma: long-term follow-up.

Barbesino G, Goldfarb M, Parangi S, Yang J, Ross DS, Daniels GH.

Thyroid. 2012 Apr;22(4):369-76. doi: 10.1089/thy.2011.0198. Epub 2012 Mar 2.

8.

Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.

Tuttle RM, Brokhin M, Omry G, Martorella AJ, Larson SM, Grewal RK, Fleisher M, Robbins RJ.

J Nucl Med. 2008 May;49(5):764-70. doi: 10.2967/jnumed.107.049072. Epub 2008 Apr 15.

9.

Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer.

Sohn SY, Choi JY, Jang HW, Kim HJ, Jin SM, Kim SW, Suh S, Hur KY, Kim JH, Chung JH, Kim SW.

Thyroid. 2013 Jun;23(6):741-7. doi: 10.1089/thy.2012.0136.

10.
11.

Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH.

Tala H, Robbins R, Fagin JA, Larson SM, Tuttle RM.

J Clin Endocrinol Metab. 2011 Jul;96(7):2105-11. doi: 10.1210/jc.2011-0305. Epub 2011 May 11.

PMID:
21565788
12.

Recombinant human thyroid-stimulating hormone to stimulate 131-I uptake for remnant ablation and adjuvant therapy.

Sabra MM, Tuttle RM.

Endocr Pract. 2013 Jan-Feb;19(1):149-56. doi: 10.4158/EP12278.RA. Review.

PMID:
23186980
13.

Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.

Vianello F, Mazzarotto R, Mian C, Lora O, Saladini G, Servodio O, Basso M, Pennelli G, Pelizzo MR, Sotti G.

Clin Oncol (R Coll Radiol). 2012 Apr;24(3):162-8. doi: 10.1016/j.clon.2011.02.011. Epub 2011 Mar 15.

PMID:
21411300
15.

Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.

Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, Mete M, Jonklaas J, Wartofsky L.

Thyroid. 2012 Mar;22(3):310-7. doi: 10.1089/thy.2011.0235. Epub 2012 Feb 7.

17.

Absence of bone marrow toxicity in elderly patients treated with recombinant human thyroid-stimulating hormone and empirically dosed radioiodine for thyroid cancer.

Amdur RJ, Dan T, Mazzaferri E.

Am J Clin Oncol. 2013 Aug;36(4):348-53. doi: 10.1097/COC.0b013e318248d67c.

PMID:
22547013
18.
19.

Serum thyroglobulin level after radioiodine therapy (Day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer.

Kim YI, Im HJ, Paeng JC, Cheon GJ, Kang KW, Lee DS, Joon Park D, Park YJ, Chung JK.

Ann Nucl Med. 2015 Feb;29(2):184-9. doi: 10.1007/s12149-014-0927-5. Epub 2014 Nov 18.

PMID:
25404419
20.

Supplemental Content

Support Center